Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry


ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Research Article

Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes

Author(s): Gerd Ludwig, Marija Mojić, Mirna Bulatović, Sanja Mijatović, Danijela Maksimović-Ivanić, Dirk Steinborn and Goran N. Kaluđerović

Volume 16, Issue 11, 2016

Page: [1455 - 1460] Pages: 6

DOI: 10.2174/1871520615666151029100749

Price: $65


In vitro studies with the ruthenium(II) and analogous iridium(III) complexes [Ru(η6- p-cymene)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}], [Ru(η6-p-cymene)Cl{Ph2PCH2CH2CH2S(O)xPh- κP,κS}][PF6] (1–4), [Ir(η5-C5Me5)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}] and [Ir(η5-C5Me5)Cl{Ph2 PCH2CH2CH2S(O)xPh-κP,κS}][PF6] (5–8; x = 0, 1) revealed the high selectivity toward the 8505C, A253, MCF-7, SW480 and 518A2 cancer cell lines. Thus, the cationic ruthenium complex 4 proved to be the most selective one. In case of the neutral and cationic ruthenium complexes 1–4 the caspase-dependent apoptotic cell death was proven as the main cause of the drug’s tumoricidal action on 8505C cell line.

Keywords: Apoptosis, autophagy, caspase, cisplatin, iridium(III) complexes, ruthenium(II) complexes.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy